Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer

KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients

FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer

Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy

Pfizer and Astellas report groundbreaking results in muscle-invasive bladder cancer trial

Thermo Fisher launches genetic test to personalize transplant drug dosing

The TacroType test provides actionable genetic insights to help clinicians understand how individual patients metabolize tacrolimus

Eli Lilly’s orforglipron outshines oral semaglutide in landmark diabetes trial

The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints

Combination therapy cuts death Risk in advanced prostate cancer: PEACE-3 trial

PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer

Star Health & Allied Insurance rolls out 32 free primary care clinics across 9 states

The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives

Novo Nordisk slashes prices of Wegovy & Ozempic by up to 50%

The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients

Pfizer bags rull FDA nod for BRAFTOVI combination in aggressive colorectal cancer

BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results

Novo Nordisk & Vivtex team up to revolutionize oral hiologics

Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk